About the Company:  Albireo Parma operates as a biopharmaceutical company that focuses on the development and commercialization of novel bile acid modulators which is used to treat orphan pediatric liver diseases and gastrointestinal disorders. The company is located in Boston, Massachusetts.

Stock Analysis: NASDAQ: ALBO at  (Stock Symbol of Albireo Pharma) has shown the peak performance at the end of the month of June (considering the duration of the last 3 months). During the peak performance, the price was 29.92, and the volume was 63.11K. The Opening 11:53 08/18 EDT was 27.65, and the previous close was at the same price of 26.98. The Market Capital at that time was 414.49M and the low for the time being was 26.53, the high being the same at 27.15. While the 52-week low was 11.26 and the 52-week high was found to be 31.50.

The price/earnings ratio (often referred to as p/E or TTM) is –4.664. Coming to the portion of the field by which the stocks are distributed, if we refer to the same time when the stock was opened (I.e. 11:53 08/18 EDT), it is observed that in the Biological and Medical Research, the stock value decreased by a percentage of 0.92. And in the Pharmaceutical and Medical Research, the stock value decreased by a percentage of 0.41.

If we analyze the EPS (earnings per share), it is observed that until the duration of March, the EPS was found to be $2.23 and until the month of June, it was observed to be $1.35. So, if we consider the opinion of some of the analysts in order to see what should be done regarding the stocks of Albireo Pharma, many are in the favor of holding and while some favor to buy it strongly. Also, this is pretty clear from the analysis of the stock price of Albireo Pharma that since the company is running in profit, the stock price has increased. Also, in the current period the opening is comparable to its maximum in the duration of 1 month (27.60 at this period while the maximum being 2.60).

Some of the Company’s catching points: Albireo Pharma serves patients which are residing in the United States. Albireo’s candidate for the leading product, A4250, is mainly directed to treat rare pediatric cholestatic liver diseases and is currently in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo’s elobixibat, is the first ileal bile acid transporter (IBAT) inhibitor, approved anywhere in the world which Is approved for the treatment of chronic constipation. You can do stock trading from stock app with option function.

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.